Skip to main content
Premium Trial:

Request an Annual Quote

BD to Acquire Atto Bioscience in $25M Cash Deal

NEW YORK, July 1 (GenomeWeb News) - BD Biosciences, a division of Becton, Dickinson and Co., today announced the purchase of Atto Bioscience of Rockville, Md., in a cash transaction valued at approximately $25 million, the company said in a statement.


Atto is a high-content cell analysis imaging tools developer with sales of $3 million in 2003.


BD is buying the firm with the goal of integrating Atto's imaging platforms and BD's flow cytometry tools, the company said.





The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.